Rifampin in Leishmaniasis
- 1 November 1977
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 113 (11) , 1610-1611
- https://doi.org/10.1001/archderm.1977.01640110130031
Abstract
To the Editor.— I was very interested in the letter by Griffiths and Sodeify (Arch Dermatol 112:1791, 1976) in which rifampin is mentioned as a valuable drug for the treatment of cutaneous leishmaniasis. I would like to report the case of a 19-year-old woman who had a 4 × 4-cm ulcer of eight months' duration on the right forearm. On October 1976, a Giemsa stain revealed Leishman-Donovan bodies on a smear obtained from the base of the ulcer. The patient was started on a pentavalent antimonial compound, methylglucamine antimoniate (Glucantime [France]; no comparable US product); she received two courses, (ten injections of 1.5 gm each) during a period of four weeks, without any signs of improvement. After reading the above-mentioned letter, I decided to start her on a regimen of rifampin, 600 mg twice a day for ten days; complete healing of the lesion with this treatment was observed. IfThis publication has 0 references indexed in Scilit: